Related Experiment Video
Updated: Dec 20, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Targeted Therapies for Eosinophilic Gastrointestinal Disorders
Alfredo J Lucendo1,2,3, Piedad López-Sánchez4
1Department of Gastroenterology, Hospital General de Tomelloso, Vereda de Socuéllamos, s/n.,, 13700, Tomelloso, Ciudad Real, Spain. ajlucendo@hotmail.com.
Eosinophilic gastrointestinal disorders require novel treatments beyond diet and steroids due to high recurrence and refractoriness. Targeted therapies like monoclonal antibodies show promise for managing these complex conditions.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Eosinophilic gastrointestinal disorders (EGIDs) present treatment challenges, including refractoriness and recurrence, necessitating new therapeutic approaches.
- Pathophysiological mechanisms of EGIDs, particularly eosinophilic esophagitis (EoE), share similarities with atopic conditions.
Purpose of the Study:
- To review current limitations in EGID treatment and explore emerging targeted therapies.
- To highlight novel therapeutic strategies for eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC).
Main Methods:
- Review of current literature on EGID pathophysiology and treatment.
- Analysis of ongoing clinical trials for novel targeted therapies in EoE and EGE.
Main Results:
- Current treatments (diet, corticosteroids) for EGIDs are limited by refractoriness and recurrence.
- Monoclonal antibodies targeting IL-13 (cendakimab) and IL-4 (dupilumab) are in Phase 3 trials for EoE.
- Anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) show potential for EGE.
Conclusions:
- Novel targeted therapies, including monoclonal antibodies and other pathway inhibitors, offer new hope for managing EGIDs.
- Further investigation into JAK-STAT and CRTH2 pathway inhibition is warranted for EGID treatment.
More Related Videos
10:15Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation
Published on: March 22, 2017
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...